I agree, the safety data is unlikely to have a significant effect on the SP in the short term, but's it's another important step in the development/approval process.
It also helps open the door to an early FDA approval should the Phase 111 trial interim efficacy data show significant results. A long shot, yes but possible nevertheless.
anyone roughly know when the next ann. is due?, page-12
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
0.005(1.59%) |
Mkt cap ! $458.1M | |||
| Open | High | Low | Value | Volume |
| 31.5¢ | 32.0¢ | 31.0¢ | $378.4K | 1.198M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 24 | 378079 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 53404 | 10 |
View Market Depth
| Last trade - 12.31pm 19/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |